ABBV AbbVie Inc. Common Stock
$263,81
Harga · Agu 21, 2026
Fundamental per Agu 3, 2026
Rentang 52M
$191–$267
95% of range
Peringkat Analis
BUY
38 analysts
Target Harga
$276
+5% upside
P/E (TTM)
96.8
ROE
15367.3%
Margin Laba Bersih
6.9%
Tentang AbbVie Inc. Common Stock Tinjauan perusahaan dari Wikipedia
AbbVie adalah sebuah perusahaan biofarmasi publik asal Amerika yang didirikan pada tahun 2013. Perusahaan ini berasal dari pemisahan Abbott Laboratories.
Baca selengkapnya
AbbVie adalah sebuah perusahaan biofarmasi publik asal Amerika yang didirikan pada tahun 2013. Perusahaan ini berasal dari pemisahan Abbott Laboratories.
Sejarah
Pada tanggal 19 Oktober 2011, Abbott Laboratories mengumumkan rencana untuk membagi organisasinya menjadi dua perusahaan publik. Abbott Laboratories akan fokus pada produk terdiversifikasi, seperti alat kesehatan, peralatan diagnostik, dan produk nutrisi, sementara AbbVie akan beroperasi sebagai sebuah produsen farmasi berbasis riset. Pemisahan tersebut akhirnya mulai berlaku pada tanggal 1 Januari 2013, dan AbbVie pun resmi melantai di Bursa Saham New York (ABBV) keesokan harinya.
Menurut Miles White, CEO pada saat itu, tujuan pemisahan adalah untuk memungkinkan pasar menilai dua perusahaan tersebut secara terpisah. Sejumlah investor khawatir bahwa pemisahan tersebut dilakukan untuk melindungi nilai bisnis alat kesehatan dari berkurangnya nilai divisi obat akibat paten Humira yang akan kedaluwarsa, padahal Humira menyumbang sekitar separuh dari pendapatan divisi obat.
Hingga bulan Desember 2015, perusahaan ini mempekerjakan 28.000 orang di seluruh dunia, dan menyediakan produk untuk individu di lebih dari 170 negara.
Pada bulan Maret 2020, saat pandemi COVID-19 berkembang menjadi sebuah krisis internasional, pemerintah Israel mengumumkan bahwa mereka akan menekan AbbVie untuk melisensikan patennya atas Kaletra, nama merek dari lopinavir/ritonavir, sebuah medikasi kombinasi dosis tetap untuk mengobati dan mencegah HIV/AIDS yang diduga memiliki sejumlah kecocokan untuk melawan COVID-19. Sebagai tanggapan, AbbVie mengumumkan bahwa mereka akan berhenti menegakkan paten atas semua obatnya.
Akuisisi
Pada bulan Januari 2014, perusahaan ini resmi mengakuisisi ImmuVen. Pada tanggal 3 September 2014, AbbVie dan Infinity Pharmaceuticals mengumumkan bahwa mereka telah menjalin kolaborasi global untuk mengembangkan dan mengkomersialisasikan duvelisib, penghambat PI3K buatan Infinity untuk mengobati pasien kanker. Pada hari yang sama, AbbVie dan Calico mengumumkan bahwa mereka telah menjalin kolaborasi riset dan pengembangan untuk menciptakan, mengembangkan, dan membawa terapi baru untuk para penderita penyakit yang terkait dengan usia, seperti neurodegenerasi dan kanker. California Life Company, beroperasi dengan nama Calico, adalah anak usaha Alphabet Inc. yang fokus pada penyakit yang terkait dengan usia dan penuaan. Calico dipimpin oleh mantan chairman dan CEO Genentech, Arthur D. Levinson serta mantan EVP dan direktur medis Genentech, Hal V. Barron.
Pada bulan Oktober 2014, setelah lama bernegosiasi, AbbVie menghentikan upayanya untuk mengakuisisi Shire, yang andai terjadi akan menjadi salah satu kesepakatan akuisisi terbesar pada tahun 2014, dan menjadi salah satu inversi pajak terbesar dalam sejarah, karena adanya perubahan peraturan perpajakan dari Departemen Keuangan Amerika Serikat membuat AbbVie harus membayar biaya perpisahan sebesar $1,6 miliar.
Pada tanggal 4 Maret 2015, AbbVie mengumumkan bahwa mereka telah setuju untuk mengakuisisi perusahaan onkologi Pharmacyclics dan obat kanker darahnya, ibrutinib. AstraZeneca sebelumnya juga telah mengajukan tawaran untuk mengakuisisi Pharmacyclics. Pada akuisisi tersebut, AbbVie setuju untuk membayar $261,25 per lembar saham Pharmacyclics, dan akuisisi senilai $21 miliar tersebut akhirnya selesai pada tanggal 26 Mei 2015. Nama Pharmacyclics tetap dipertahankan, dan beroperasi sebagai anak usaha dari AbbVie. Pada tanggal 3 Juni 2015, AbbVie dan Halozyme Therapeutics mengumumkan bahwa mereka telah menjalin kolaborasi global dan perjanjian lisensi untuk mengembangkan dan mengkomersialisasikan produk yang menggabungkan obat buatan AbbVie dan teknologi pengantaran obat ENHANZE buatan Halozyme. Kolaborasi tersebut akhirnya dihentikan pada bulan November 2016.
Pada tanggal 28 April 2016, perusahaan ini mengumumkan bahwa mereka akan mengakuisisi Stemcentrx dengan harga $9,8 miliar. Keesokan harinya, perusahaan ini mengumumkan perluasan kesepakatan fibrosis kistik dengan Galapagos, yang berpotensi menggandakan pembayaran bertahap menjadi $600 juta.
Pada tanggal 25 Juni 2019, AbbVie mengumumkan bahwa mereka akan mengakuisisi Allergan plc asal Irlandia dengan harga $63 miliar. Namun transaksi tersebut tidak akan dijalankan sebagai sebuah inversi pajak, dan pasca transaksi tersebut, AbbVie (dan anak usahanya) akan tetap berdomisili di Amerika Serikat untuk tujuan perpajakan; Akuisisi AbbVie terhadap Allergan plc akhirnya disetujui oleh Federal Trade Commission pada tanggal 4 September 2020 dengan beberapa syarat. Pada bulan Juli 2019, perusahaan ini mengumumkan bahwa mereka akan mengakuisisi Mavupharma, untuk memperkuat portofolio obat kankernya.
Sejarah akuisisi
Kolaborasi
Pada tanggal 10 Februari 2016, AbbVie dan Synlogic asal Cambridge, Massachusetts mengumumkan sebuah kolaborasi riset dan pengembangan tahun jamak. Synlogic adalah sebuah perusahaan biologi sintetis yang didirikan berdasarkan riset dari James Collins dan Tim Lu di MIT. Sebagai bagian dari kolaborasi tersebut, AbbVie mendapat hak atas teknologi berbasis probiotik buatan Synlogic untuk mengobati penyakit radang usus. Tim riset akan fokus pada penyakit Crohn dan kolitis ulseratif. Pada bulan April 2016, perusahaan ini resmi bermitra dengan Universitas Chicago untuk menginvestigasi sejumlah bidang onkologi, yakni kanker payudara, paru-paru, prostat, usus besar, dan darah. Pada bulan yang sama, perusahaan ini mengumumkan bahwa mereka akan ikut mengkomersialisasikan imunoterapi praklinis ARGX-115 buatan Argenx. ARGX-115 adalah imunoterapi pertama di kelasnya yang menargetkan GARP (glycoprotein A repetitions predominant), sebuah protein membran yang dipercaya dapat menambah dampak imunosupresif dari sel T. Perusahaan ini juga mengumumkan kesepakatan untuk ikut mengembangkan / mengkomersialisasikan setidaknya satu konjugat buatan CytomX Probody untuk melawan CD71 (reseptor transferin 1).
Referensi
Pranala luar
Media terkait AbbVie Inc. di Wikimedia Commons
Data bisnis AbbVie:
Sumber: Wikipedia, CC BY-SA 4.0 · Lihat di Wikipedia ↗
ABBV Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$263.81
Kapitalisasi Pasar
—
P/E (TTM)
96.8
EPS (TTM)
$2.36
Pendapatan (TTM)
$61.16B
Imbal Hasil Dividen
—
ROE
15367.3%
D/E Utang/Ekuitas
-0.8
Rentang 52M
$191 – $267
ABBV Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
$61.16B
2016-12-31
→
2025-12-31
EPS
$2.36
2016-12-31
→
2025-12-31
Arus Kas Bebas
$17.82B
2016-12-31
→
2025-12-31
Margin
6.9%
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
ABBV
Median Rekan
P/E (TTM)
96.8
24.7
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
ABBV
Median Rekan
Operating Margin (Margin Operasi)
24.6%
—
Net Profit Margin (Margin Laba Bersih)
6.9%
17.4%
ROA
3.1%
6.7%
ROE
15367.3%
18.8%
ROIC
-1254.6%
—
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
ABBV
Median Rekan
Debt / Equity (Utang / Ekuitas)
-0.8
—
Current Ratio (Rasio Lancar)
0.7
3.1
Quick Ratio (Rasio Cepat)
0.4
—
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
ABBV
Median Rekan
Revenue YoY (Pendapatan YoY)
8.6%
—
Revenue CAGR 3Y (CAGR Pendapatan 3T)
1.8%
—
Revenue CAGR 5Y (CAGR Pendapatan 5T)
5.9%
—
EPS YoY
-1.3%
—
Net Income YoY (Laba Bersih YoY)
-1.2%
—
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
ABBV
Median Rekan
Payout Ratio (Rasio Pembayaran Dividen)
275.8%
—
Dividen Yield, rasio pembayaran, riwayat dividen, CAGR 5 tahun
Imbal Hasil Dividen
—
Rasio Pembayaran Dividen
275.8%
CAGR Dividen 5T
—
| Tanggal ex-dividen | Jumlah |
|---|---|
| 15 Juli 2026 | $1,7300 |
| 15 April 2026 | $1,7300 |
| 16 Jan. 2026 | $1,7300 |
| 15 Okt. 2025 | $1,6400 |
| 15 Juli 2025 | $1,6400 |
| 15 April 2025 | $1,6400 |
| 15 Jan. 2025 | $1,6400 |
| 15 Okt. 2024 | $1,5500 |
| 15 Juli 2024 | $1,5500 |
| 12 April 2024 | $1,5500 |
| 12 Jan. 2024 | $1,5500 |
| 12 Okt. 2023 | $1,4800 |
| 13 Juli 2023 | $1,4800 |
| 13 April 2023 | $1,4800 |
| 12 Jan. 2023 | $1,4800 |
| 13 Okt. 2022 | $1,4100 |
| 14 Juli 2022 | $1,4100 |
| 13 April 2022 | $1,4100 |
| 13 Jan. 2022 | $1,4100 |
| 14 Okt. 2021 | $1,3000 |
ABBV Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
BELI
38 analis
- Beli Kuat 9 23,7%
- Beli 22 57,9%
- Tahan 7 18,4%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
29 analis · 2026-08-18
Median
$280.00
Sekarang
$263.81
Rendah
$200.00
Tinggi
$328.00
Target median
$280.00
+6,1%
Target rata-rata
$276.41
+4,8%
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
0.01%
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $3.65 | $3.68 | -0.03% |
| 31 Maret 2026 | $2.65 | $2.65 | 0.00% |
| 31 Des. 2025 | $2.71 | $2.71 | 0.00% |
| 30 Sep. 2025 | $1.86 | $1.81 | 0.05% |
| 30 Juni 2025 | $2.97 | $2.94 | 0.03% |
| 31 Maret 2025 | $2.46 | $2.43 | 0.03% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| ABBV | — | 96.8 | 8.6% | 6.9% | 15367.3% | — |
| AMGN | $176.35B | 23.0 | 10.0% | 21.0% | 95.9% | — |
| GILD | $152.32B | 18.1 | 2.4% | 28.9% | 40.5% | — |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 15
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | |
| Cost of Revenue | $18.20B | $16.90B | $20.41B | $17.41B | $17.45B | $15.39B | $7.44B | $7.72B | $7.04B | $5.83B | $4.50B | $4.43B | |
| SG&A Expense | $14.01B | $14.75B | $12.87B | $15.26B | $12.35B | $11.30B | $6.94B | $7.40B | $6.29B | $5.88B | $6.39B | $7.72B | |
| Operating Expenses | $46.09B | $47.20B | $41.56B | $39.94B | $38.27B | $34.44B | $20.28B | $26.37B | $18.67B | $16.30B | $15.32B | $16.55B | |
| Operating Income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.54B | $9.34B | $7.54B | $3.41B | |
| Interest Expense | $2.89B | $2.81B | $2.22B | $2.23B | $2.42B | $2.45B | $1.78B | $1.35B | $1.15B | $1.05B | $719M | $429M | |
| Other Non-op | $-5.79B | $-3.24B | $-4.68B | $-2.45B | $-2.50B | $-5.61B | $-3.01B | $-18M | $-466M | $-188M | $-13M | $27M | |
| Pretax Income | $6.60B | $3.72B | $6.25B | $13.48B | $12.99B | $3.40B | $8.43B | $5.20B | $7.73B | $7.88B | $6.64B | $2.37B | |
| Income Tax | $2.36B | $-570M | $1.38B | $1.63B | $1.44B | $-1.22B | $544M | $-490M | $2.42B | $1.93B | $1.50B | $595M | |
| Net Income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | |
| EPS (Basic) | $2.37 | $2.40 | $2.73 | $6.65 | $6.48 | $2.73 | $5.30 | $3.67 | $3.31 | $3.65 | $3.15 | $1.11 | |
| EPS (Diluted) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 | $3.30 | $3.63 | $3.13 | $1.10 | |
| Shares (Basic) | 1,769,000,000 | 1,769,000,000 | 1,768,000,000 | 1,771,000,000 | 1,770,000,000 | 1,667,000,000 | 1,481,000,000 | 1,541,000,000 | 1,596,000,000 | 1,622,000,000 | 1,625,000,000 | 1,595,000,000 | |
| Shares (Diluted) | 1,773,000,000 | 1,773,000,000 | 1,773,000,000 | 1,778,000,000 | 1,777,000,000 | 1,673,000,000 | 1,484,000,000 | 1,546,000,000 | 1,603,000,000 | 1,631,000,000 | 1,637,000,000 | 1,610,000,000 | |
| EBITDA | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.59B | $9.38B | $7.54B | $3.41B |
Neraca 26
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.23B | $5.52B | $12.81B | $9.20B | $9.75B | $8.45B | $39.92B | $7.29B | $9.30B | $5.10B | $8.40B | $8.35B | |
| Short-term Investments | $28M | $31M | $2M | $28M | $84M | $30M | $0 | $772M | $486M | $1.32B | $8M | $26M | |
| Receivables | $12.59B | $10.92B | $11.15B | $11.25B | $9.98B | $8.82B | $5.43B | $5.38B | $5.09B | $4.76B | $4.73B | · | |
| Inventory | $4.95B | $4.18B | $4.10B | $3.58B | $3.13B | $3.31B | $1.81B | $1.60B | $1.60B | $1.44B | $1.72B | $1.12B | |
| Prepaid Expense | $6.29B | · | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $29.06B | $25.58B | $33.00B | $28.46B | $27.93B | $24.17B | $49.52B | $16.95B | $21.22B | $16.19B | $16.31B | $16.08B | |
| PP&E (Net) | $5.63B | $5.13B | $4.99B | $4.93B | $5.11B | $5.25B | $2.96B | $2.88B | $2.80B | $2.60B | $2.56B | $2.48B | |
| PP&E (Gross) | $13.53B | $12.27B | $11.63B | $10.99B | $10.73B | $10.86B | $8.19B | $8.40B | $8.07B | $7.53B | $7.33B | $7.11B | |
| Accum. Depreciation | $7.90B | $7.13B | $6.65B | $6.05B | $5.62B | $5.61B | $5.23B | $5.51B | $5.27B | $4.92B | $4.77B | $4.62B | |
| Goodwill | $35.64B | $34.96B | $32.29B | $32.16B | $32.38B | $33.12B | $15.60B | $15.66B | $15.79B | $15.42B | $13.17B | $5.86B | |
| Intangibles | $52.64B | $60.07B | $55.61B | $67.44B | $75.95B | $82.88B | $18.65B | $21.23B | $27.56B | $28.90B | $19.71B | $1.51B | |
| Other Non-current Assets | $10.72B | $9.14B | $8.51B | $5.57B | $4.88B | $4.85B | $2.29B | $1.21B | $1.33B | $1.21B | $1.15B | $1.48B | |
| Total Assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B | $59.35B | $70.79B | $66.10B | $53.05B | $27.51B | |
| Accounts Payable | $34.73B | $2.94B | $3.69B | $2.93B | $2.88B | $2.28B | $1.45B | $1.55B | $1.47B | $1.41B | $1.60B | $1.40B | |
| Short-term Debt | $2.50B | $0 | $0 | $1M | $14M | $34M | $0 | $3.70B | $400M | $377M | $406M | $425M | |
| Current Liabilities | $43.29B | $38.75B | $37.84B | $29.54B | $35.19B | $28.66B | $15.59B | $17.24B | $16.64B | $9.78B | $10.89B | $11.39B | |
| Capital Leases | $689M | $697M | $735M | $754M | $713M | $832M | · | · | · | · | · | · | |
| Deferred Tax | $2.39B | $2.58B | $1.95B | $2.19B | $3.01B | $3.65B | $1.13B | $1.07B | $2.49B | $6.89B | $5.28B | $159M | |
| Other Non-current Liabilities | $32.57B | $30.13B | $32.33B | $30.66B | $28.70B | $27.61B | $17.60B | $1.31B | $1.24B | $1.16B | $844M | $990M | |
| Long-term Debt | $64.50B | $66.84B | $59.24B | $63.13B | $75.96B | $84.95B | $67.23B | · | · | · | · | · | |
| Total Debt | $2.50B | · | $0 | $1M | $14M | $34M | $0 | $3.70B | $400M | $377M | $406M | $425M | |
| Retained Earnings | $-15.49B | $-7.90B | $-1.00B | $4.78B | $3.13B | $1.05B | $4.72B | $3.37B | $5.46B | $4.38B | $2.25B | $535M | |
| Treasury Stock | $9.15B | $8.20B | $6.53B | $4.59B | $3.14B | $2.26B | $24.50B | $24.11B | $11.92B | $10.85B | $8.84B | $972M | |
| AOCI | $-1.14B | $-1.93B | $-2.31B | $-2.20B | $-2.90B | $-3.12B | $-3.60B | $-2.48B | $-2.73B | $-2.59B | $-2.56B | $-2.03B | |
| Stockholders' Equity | $-3.27B | $3.33B | $10.36B | $17.25B | $15.41B | $13.08B | $-8.17B | $-8.45B | $5.10B | $4.64B | $3.94B | $1.74B | |
| Liabilities + Equity | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B | $59.35B | $70.79B | $66.10B | $53.05B | $27.51B |
Arus Kas 17
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $955M | $911M | $747M | $671M | $692M | $753M | $430M | $421M | $365M | $353M | $282M | $241M | |
| Deferred Tax | $-492M | $-1.45B | $-2.89B | $-1.93B | $-898M | $-2.33B | $122M | $-1.52B | $-4.16B | $-796M | $152M | $-380M | |
| Amort. of Intangibles | $7.38B | $7.62B | $7.95B | $7.69B | $7.72B | $5.80B | $1.55B | $1.29B | $1.08B | $764M | $419M | $403M | |
| Restructuring | · | · | · | · | · | · | $219M | $59M | $86M | $52M | $126M | $16M | |
| Operating Cash Flow | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B | $17.59B | $13.32B | $13.43B | $9.96B | $7.04B | $7.54B | $3.55B | |
| CapEx | $1.21B | $974M | $777M | $695M | $787M | $798M | $552M | $638M | $529M | $479M | $532M | $612M | |
| Investing Cash Flow | $-6.64B | $-20.82B | $-2.01B | $-623M | $-2.34B | $-37.56B | $596M | $-1.01B | $-274M | · | · | · | |
| Debt Issued | $3.99B | $16.96B | · | $2.00B | $1.00B | $3.00B | $31.48B | $5.96B | $0 | $11.63B | $20.66B | · | |
| Net Debt Issued | $3.99B | $16.96B | · | $2.00B | $1.00B | $3.00B | $31.48B | $5.96B | $0 | $11.63B | $20.66B | · | |
| Stock Repurchased | $980M | $1.71B | $1.97B | $1.49B | $934M | $978M | $629M | $12.01B | $1.41B | $6.03B | $7.59B | $665M | |
| Net Stock Activity | $-980M | $-1.71B | $-1.97B | $-1.49B | $-934M | $-978M | $-629M | $-12.01B | $-1.41B | $-6.03B | $-7.57B | $-652M | |
| Dividends Paid | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B | $3.29B | $2.66B | |
| Financing Cash Flow | $-12.72B | $-5.21B | $-17.22B | $-24.80B | $-19.04B | $-11.50B | $18.71B | $-14.40B | $-5.51B | $-3.93B | · | · | |
| Net Change in Cash | $-295M | $-7.29B | $3.61B | $-545M | $1.30B | $-31.48B | $32.63B | $-2.01B | $4.20B | $-3.30B | $51M | $-1.25B | |
| Taxes Paid | $3.63B | $4.10B | $4.70B | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B | $16.79B | $12.77B | $12.79B | $9.43B | $6.56B | $7.00B | $2.94B | |
| Levered FCF | $15.96B | $14.59B | $20.33B | $22.29B | $19.84B | $13.45B | $11.10B | $11.31B | $8.64B | $5.77B | $6.45B | $2.62B |
Profitabilitas 7
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 34.0% | 36.6% | 33.0% | 17.1% | |
| Net Margin | 6.9% | 7.6% | 8.9% | 20.4% | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% | · | · | |
| Pretax Margin | 10.8% | 6.6% | 11.5% | 23.2% | 23.1% | 7.4% | 25.3% | 15.9% | 27.4% | 30.8% | 29.1% | 11.9% | |
| EBITDA Margin | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 34.0% | 36.6% | 33.0% | 17.1% | |
| ROA | 3.1% | 3.2% | 3.6% | 8.3% | 7.8% | 3.9% | 10.6% | 8.7% | 7.8% | 10.0% | · | · | |
| ROE | 15367.3% | 62.5% | 35.2% | 72.5% | 81.0% | 188.2% | -94.2% | -100.1% | 109.1% | 138.8% | · | · | |
| ROIC | -1254.6% | 317.0% | 96.0% | 92.3% | 103.3% | 117.9% | -148.6% | -147.1% | 119.9% | 141.3% | 134.1% | 117.9% |
Likuiditas & Solvabilitas 4
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.7 | 0.7 | 0.9 | 1.0 | 0.8 | 0.8 | 3.2 | 1.0 | 1.3 | 1.7 | 1.5 | 1.4 | |
| Quick Ratio | 0.4 | 0.4 | 0.6 | 0.7 | 0.6 | 0.6 | 2.9 | 0.8 | 0.6 | 0.7 | 0.8 | 0.7 | |
| Debt / Equity | -0.8 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.4 | 0.1 | 0.1 | 0.1 | 0.2 | |
| Interest Coverage | 5.2 | 3.3 | 5.7 | 8.1 | 7.4 | 4.6 | 7.3 | 4.7 | 8.3 | 9.0 | 10.5 | 8.0 |
Efisiensi 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.6 | 0.7 | |
| Inventory Turnover | 4.0 | 4.1 | 5.3 | 5.2 | 5.4 | 6.0 | 4.4 | 4.8 | 4.6 | 3.7 | 3.2 | 3.9 | |
| Receivables Turnover | 5.2 | 5.1 | 4.8 | 5.5 | 6.0 | 6.4 | 6.2 | 6.3 | · | · | · | · |
Tingkat Pertumbuhan 10
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 8.6% | 3.7% | -6.4% | 3.3% | 22.7% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 1.8% | 0.08% | 5.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 5.9% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -1.3% | -12.1% | -59.0% | 2.8% | 137.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -29.1% | -28.2% | 0.00% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -2.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -1.2% | -12.0% | -58.9% | 2.5% | 150.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -29.1% | -28.2% | 1.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -1.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 8.6% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM) 6
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B | $22.86B | $19.96B | |
| Net Income TTM | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B | $5.14B | $1.77B | |
| P/E | 96.8 | 74.4 | 57.0 | 24.4 | 21.0 | 39.4 | 16.8 | 25.2 | 29.3 | 17.3 | 18.9 | 59.5 | |
| Earnings Yield | 1.0% | 1.3% | 1.8% | 4.1% | 4.8% | 2.5% | 6.0% | 4.0% | 3.4% | 5.8% | 5.3% | 1.7% | |
| Payout Ratio | 275.8% | 257.7% | 216.7% | 84.9% | 80.2% | 167.2% | 80.8% | 98.1% | 77.4% | 62.4% | · | · | |
| Annual Payout | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B | $3.29B | $2.66B |
Laporan Laba Rugi 17
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B | $13.34B | $15.10B | $14.46B | $14.46B | $12.31B | $14.30B | $13.93B | $13.87B | $12.22B | $15.12B | $14.81B | |
| Cost of Revenue | $4.29B | $4.22B | $4.55B | $5.30B | $4.35B | $4.00B | $4.40B | $4.21B | $4.20B | $4.09B | $5.70B | $6.49B | $4.24B | $3.99B | $4.17B | $5.02B | |
| Gross Profit | · | · | $12.07B | · | · | · | $10.71B | · | · | · | $8.60B | · | · | · | $10.95B | · | |
| SG&A Expense | $3.63B | $3.58B | $3.90B | $3.57B | $3.25B | $3.29B | $3.85B | $4.21B | $3.38B | $3.31B | $3.19B | $3.37B | $3.27B | $3.04B | $3.42B | $3.30B | |
| Operating Expenses | $10.56B | $11.01B | $12.07B | $13.87B | $10.53B | $9.61B | $16.59B | $10.63B | $10.46B | $9.51B | $11.11B | $11.65B | $9.35B | $9.46B | $9.62B | $10.21B | |
| Operating Income | $6.43B | $3.99B | $4.54B | $1.90B | $4.89B | $3.73B | $-1.49B | $3.83B | $4.00B | $2.80B | $3.19B | $2.28B | $4.51B | $2.77B | $5.50B | $4.60B | |
| Interest Expense | $746M | $717M | $714M | $739M | $740M | $700M | $702M | $720M | $726M | $660M | $564M | $555M | $552M | $553M | $566M | $560M | |
| Interest Income | $67M | $72M | · | $72M | $62M | $73M | · | $129M | $220M | $207M | · | $157M | $98M | $99M | · | $63M | |
| Other Non-op | $-1.48B | $-2.31B | $-1.21B | $-503M | $-2.66B | $-1.45B | $-150M | $-1.16B | $-1.34B | $-586M | $-1.56B | $95M | $-1.41B | $-1.80B | $-2.02B | $330M | |
| Pretax Income | $4.28B | $1.04B | $2.67B | $714M | $1.55B | $1.66B | $-2.27B | $2.08B | $2.15B | $1.75B | $1.21B | $1.95B | $2.61B | $475M | $2.96B | $4.40B | |
| Income Tax | $662M | $342M | $853M | $526M | $613M | $372M | $-2.25B | $520M | $773M | $383M | $388M | $172M | $583M | $234M | $493M | $448M | |
| Net Income | $3.61B | $695M | $1.82B | $186M | $938M | $1.29B | $-22M | $1.56B | $1.37B | $1.37B | $822M | $1.78B | $2.02B | $239M | $2.47B | $3.95B | |
| EPS (Basic) | $2.04 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | $-0.02 | $0.88 | $0.77 | $0.77 | $0.46 | $1.00 | $1.14 | $0.13 | $1.39 | $2.22 | |
| EPS (Diluted) | $2.03 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | $-0.03 | $0.88 | $0.77 | $0.77 | $0.45 | $1.00 | $1.14 | $0.13 | $1.40 | $2.21 | |
| Shares (Basic) | 1,769,000,000 | 1,770,000,000 | -3,536,000,000 | 1,769,000,000 | 1,768,000,000 | 1,768,000,000 | -3,537,000,000 | 1,769,000,000 | 1,768,000,000 | 1,769,000,000 | -3,536,000,000 | 1,767,000,000 | 1,767,000,000 | 1,770,000,000 | -3,541,000,000 | 1,771,000,000 | |
| Shares (Diluted) | 1,771,000,000 | 1,774,000,000 | -3,542,000,000 | 1,772,000,000 | 1,771,000,000 | 1,772,000,000 | -3,543,000,000 | 1,772,000,000 | 1,771,000,000 | 1,773,000,000 | -3,545,000,000 | 1,771,000,000 | 1,771,000,000 | 1,776,000,000 | -3,552,000,000 | 1,776,000,000 | |
| EBITDA | $6.43B | $3.99B | · | $1.90B | $4.89B | $3.73B | · | $3.83B | $4.00B | $2.80B | · | $2.28B | $4.51B | $2.77B | · | $4.60B |
Neraca 26
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.57B | $9.39B | $5.23B | $5.63B | $6.47B | $5.17B | $5.52B | $7.26B | $13.13B | $18.07B | · | $13.29B | $8.76B | $6.71B | · | $11.83B | |
| Short-term Investments | · | · | $28M | $42M | $0 | $1M | $31M | $28M | $27M | $2M | · | $3M | $7M | $11M | · | $47M | |
| Receivables | $13.82B | $12.48B | $12.59B | $12.77B | $12.64B | $12.48B | $10.92B | $11.47B | $11.72B | $11.95B | · | $11.41B | $11.49B | $11.47B | · | $10.74B | |
| Inventory | $5.13B | $5.05B | $4.95B | $4.94B | $4.96B | $4.53B | $4.18B | $4.45B | $4.22B | $4.25B | · | $3.98B | $4.05B | $3.83B | · | $3.17B | |
| Prepaid Expense | $8.15B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $33.67B | $33.53B | $29.06B | $28.54B | $29.26B | $27.68B | $25.58B | $27.79B | $33.82B | $38.87B | · | $33.22B | $28.85B | $26.49B | · | $30.36B | |
| PP&E (Net) | $5.80B | $5.69B | $5.63B | $5.48B | $5.28B | $5.24B | $5.13B | $5.14B | $5.02B | $4.98B | · | $4.93B | $4.94B | $4.93B | · | $4.89B | |
| PP&E (Gross) | $13.96B | $13.73B | $13.53B | $13.23B | $12.93B | $12.57B | $12.27B | $12.28B | $11.90B | $11.72B | · | $11.37B | $11.32B | $11.14B | · | $10.68B | |
| Accum. Depreciation | $8.16B | $8.04B | $7.90B | $7.75B | $7.65B | $7.33B | $7.13B | $7.14B | $6.88B | $6.75B | · | $6.44B | $6.38B | $6.21B | · | $5.79B | |
| Goodwill | $35.52B | $35.57B | $35.64B | $35.63B | $35.64B | $35.28B | $34.96B | $35.30B | $33.39B | $33.43B | $32.29B | $32.09B | $32.22B | $32.22B | $32.16B | $31.73B | |
| Intangibles | $49.14B | $50.87B | $52.64B | $54.31B | $57.03B | $58.49B | $60.07B | $66.65B | $60.24B | $62.23B | · | $58.60B | $62.86B | $64.85B | · | $68.72B | |
| Other Non-current Assets | $10.73B | $10.54B | $10.72B | $9.64B | $9.66B | $9.19B | $9.14B | $8.29B | $9.20B | $9.07B | · | $7.09B | $6.20B | $5.80B | · | $5.38B | |
| Total Assets | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B | $148.87B | · | $136.22B | $135.37B | $134.54B | · | $141.32B | |
| Accounts Payable | $33.30B | $33.77B | $3.59B | $33.62B | $32.24B | $31.04B | $2.94B | $30.49B | $29.33B | $31.33B | · | $29.66B | $27.04B | $24.79B | · | $23.50B | |
| Short-term Debt | $0 | $0 | $2.50B | $3.79B | $5.56B | $1.59B | $0 | · | · | $3M | · | $2M | $0 | $1M | · | $10M | |
| Current Liabilities | $41.64B | $42.10B | $43.29B | $39.39B | $39.77B | $36.40B | $38.75B | $43.06B | $41.91B | $41.52B | · | $34.77B | $32.24B | $27.59B | · | $32.71B | |
| Capital Leases | · | · | $689M | · | · | · | $697M | · | · | · | · | · | · | · | · | · | |
| Deferred Tax | $2.28B | $2.33B | $2.39B | $2.48B | $2.55B | $2.58B | $2.58B | $2.75B | $2.73B | $2.72B | · | $2.04B | $2.12B | $2.11B | · | $1.97B | |
| Other Non-current Liabilities | $34.60B | $34.11B | $32.57B | $31.66B | $32.04B | $31.19B | $30.13B | $33.03B | $32.43B | $32.78B | · | $31.64B | $32.29B | $32.25B | · | $30.21B | |
| Long-term Debt | · | · | $64.50B | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $0 | $0 | · | $3.79B | $5.56B | $1.59B | · | · | · | $3M | · | $2M | $0 | $1M | · | $10M | |
| Retained Earnings | $-17.33B | $-17.87B | $-15.49B | $-14.23B | $-11.50B | $-9.53B | $-7.90B | $-4.96B | $-3.77B | $-2.38B | · | $933M | $1.79B | $2.39B | · | $4.95B | |
| Treasury Stock | $10.62B | $10.61B | $9.15B | $9.14B | $9.15B | $9.14B | $8.20B | $7.85B | $7.84B | $7.83B | · | $6.53B | $6.53B | $6.52B | · | $4.59B | |
| AOCI | $-1.16B | $-1.15B | $-1.14B | $-1.57B | $-1.54B | $-1.74B | $-1.93B | $-2.33B | $-2.51B | $-2.45B | · | $-2.35B | $-2.25B | $-2.23B | · | $-3.44B | |
| Stockholders' Equity | $-5.93B | $-6.66B | $-3.27B | $-2.64B | $-183M | $1.42B | $3.33B | $6.03B | $6.78B | $8.01B | · | $12.09B | $12.87B | $13.27B | · | $15.99B | |
| Liabilities + Equity | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B | $148.87B | · | $136.22B | $135.37B | $134.54B | · | $141.32B |
Arus Kas 15
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $166M | $444M | $157M | $209M | $179M | $410M | $164M | $181M | $218M | $348M | $125M | $130M | $179M | $313M | $132M | $126M | |
| Deferred Tax | $-195M | $137M | $-385M | $193M | $-272M | $-28M | $-767M | $-277M | $-16M | $-389M | $-1.39B | $-863M | $-368M | $-267M | $-516M | $-621M | |
| Amort. of Intangibles | $1.70B | $1.75B | $1.72B | $1.90B | $1.90B | $1.86B | $1.93B | $1.90B | $1.90B | $1.89B | $1.90B | $2.00B | $2.10B | $1.95B | $2.03B | $2.00B | |
| Operating Cash Flow | $3.44B | $3.83B | $5.22B | $7.02B | $5.15B | $1.64B | $7.05B | $5.45B | $2.27B | $4.04B | $4.75B | $7.57B | $6.32B | $4.19B | $7.43B | $7.60B | |
| CapEx | $322M | $265M | $329M | $381M | $269M | $235M | $291M | $249M | $241M | $193M | $205M | $219M | $178M | $175M | $213M | $177M | |
| Investing Cash Flow | $-1.20B | $-574M | $-1.46B | $-3.26B | $-1.18B | $-735M | $-1.87B | $-8.26B | $-1.10B | $-9.59B | $-800M | $-369M | $-341M | $-499M | $-448M | $1.29B | |
| Debt Issued | $0 | $7.99B | $0 | $0 | $0 | $3.99B | $2.00B | $0 | $0 | $14.96B | · | $0 | $0 | $0 | $0 | $0 | |
| Net Debt Issued | · | $7.99B | · | · | · | $3.99B | · | · | · | $14.96B | · | · | · | $0 | · | · | |
| Stock Repurchased | $9M | $1.49B | $3M | $4M | $12M | $961M | $358M | $17M | $9M | $1.32B | $3M | $4M | $10M | $1.96B | $4M | $4M | |
| Net Stock Activity | · | $-1.49B | · | · | · | $-961M | · | · | · | $-1.32B | · | · | · | $-1.96B | · | · | |
| Dividends Paid | $3.07B | $3.09B | $2.91B | $2.91B | $2.91B | $2.92B | $2.75B | $2.75B | $2.75B | $2.77B | $2.63B | $2.63B | $2.62B | $2.66B | $2.51B | $2.50B | |
| Financing Cash Flow | $-5.05B | $919M | $-4.17B | $-4.59B | $-2.71B | $-1.26B | $-6.86B | $-3.07B | $-6.10B | $10.82B | $-4.45B | $-2.66B | $-3.92B | $-6.19B | $-9.63B | $-5.52B | |
| Net Change in Cash | $-2.82B | $4.16B | $-400M | $-838M | $1.29B | $-349M | $-1.73B | $-5.87B | $-4.94B | $5.25B | $-473M | $4.53B | $2.05B | $-2.49B | $-2.63B | $3.31B | |
| Free Cash Flow | · | $3.56B | · | · | · | $1.40B | · | · | · | $3.85B | · | · | · | $4.02B | · | · | |
| Levered FCF | · | $3.08B | · | · | · | $857M | · | · | · | $3.33B | · | · | · | $3.74B | · | · |
Profitabilitas 7
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 37.9% | 26.6% | · | 12.1% | 31.7% | 28.0% | · | 26.5% | 27.6% | 22.7% | · | 16.4% | 32.6% | 22.6% | · | 31.1% | |
| Net Margin | 21.3% | 4.6% | · | 1.2% | 6.1% | 9.6% | · | 10.8% | 9.5% | 11.1% | · | 12.8% | 14.6% | 2.0% | · | 26.7% | |
| Pretax Margin | 25.2% | 6.9% | · | 4.5% | 10.1% | 12.4% | · | 14.4% | 14.8% | 14.3% | · | 14.0% | 18.8% | 3.9% | · | 29.7% | |
| EBITDA Margin | 37.9% | 26.6% | · | 12.1% | 31.7% | 28.0% | · | 26.5% | 27.6% | 22.7% | · | 16.4% | 32.6% | 22.6% | · | 31.1% | |
| ROA | 2.6% | 0.51% | · | 0.13% | 0.67% | 0.90% | · | 1.1% | 0.99% | 0.97% | · | 1.3% | 1.5% | 0.17% | · | 2.7% | |
| ROE | -118.1% | -26.6% | · | 11.0% | 28.4% | 27.3% | · | 17.2% | 14.0% | 12.9% | · | 12.7% | 14.7% | 1.6% | · | 26.7% | |
| ROIC | -91.6% | -40.2% | · | 43.7% | 55.2% | 96.2% | · | 47.7% | 37.7% | 27.3% | · | 17.2% | 27.2% | 10.6% | · | 25.8% |
Likuiditas & Solvabilitas 4
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.8 | 0.8 | · | 0.7 | 0.7 | 0.8 | · | 0.6 | 0.8 | 0.9 | · | 1.0 | 0.9 | 1.0 | · | 0.9 | |
| Quick Ratio | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.5 | · | 0.4 | 0.6 | 0.7 | · | 0.7 | 0.6 | 0.7 | · | 0.7 | |
| Debt / Equity | 0.0 | 0.0 | · | -1.4 | -30.4 | 1.1 | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Interest Coverage | 8.6 | 5.6 | · | 2.6 | 6.6 | 5.3 | · | 5.3 | 5.5 | 4.2 | · | 4.1 | 8.2 | 5.0 | · | 8.2 |
Efisiensi 3
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.9 | 0.9 | · | 1.1 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.0 | · | 1.8 | 1.1 | 1.1 | · | 1.6 | |
| Receivables Turnover | 1.3 | 1.2 | · | 1.3 | 1.3 | 1.1 | · | 1.3 | 1.2 | 1.1 | · | 1.3 | 1.2 | 1.1 | · | 1.5 |
Valuasi (TTM) 5
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $64.39B | $62.82B | · | $59.64B | $58.33B | $57.37B | · | $55.53B | $55.00B | $54.40B | · | $55.14B | $56.02B | $56.74B | · | $57.82B | |
| Net Income TTM | $6.31B | $3.63B | · | $2.39B | $3.76B | $4.20B | · | $5.12B | $5.34B | $5.99B | · | $6.51B | $8.69B | $7.58B | · | $13.41B | |
| P/E | 71.1 | 107.1 | · | 175.4 | 88.4 | 89.2 | · | 68.6 | 57.2 | 54.0 | · | 40.8 | 27.7 | 37.7 | · | 17.9 | |
| Earnings Yield | 1.4% | 0.93% | · | 0.57% | 1.1% | 1.1% | · | 1.5% | 1.8% | 1.8% | · | 2.5% | 3.6% | 2.6% | · | 5.6% | |
| Payout Ratio | · | 444.0% | · | · | · | 227.5% | · | · | · | 202.5% | · | · | · | 1113.4% | · | · |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B |
| Margin Operasi % | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% |
| Laba Bersih | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B |
| EPS Dilusian | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Utang / Ekuitas | -0.8 | — | 0.0 | 0.0 | 0.0 |
| Rasio Lancar | 0.7 | 0.7 | 0.9 | 1.0 | 0.8 |
| Rasio Cepat | 0.4 | 0.4 | 0.6 | 0.7 | 0.6 |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
- Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?
- How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?
- AbbVie Sudah Jadi Raja Dividen, Ini Alasan Akuisisi Apogee Senilai $10,9 Miliar Bisa Ciptakan Dinasti
- AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
- AbbVie (ABBV) to Acquire Apogee Therapeutics
- Is AbbVie a Buy After Its Purchase of Apogee?
- Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook
- AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
- Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B Merger
- The $11 Billion Reason Abbvie Stock Is Up Today
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 4.559 pengaju · $203.7B total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 248 (+10 vs Kuartal sebelumnya) | 102 (-73 vs Kuartal sebelumnya) | 1.873 (+177 vs Kuartal sebelumnya) | 1.507 (-178 vs Kuartal sebelumnya) | +62.9M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $29.038.274.101 | 115.396.098 | 14,25% | Saham |
| STATE STREET CORP | $20.784.645.667 | 82.596.748 | 10,20% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12.199.002.913 | 48.477.996 | 5,99% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $10.348.337.446 | 41.208.853 | 5,08% | Saham |
| Capital Research Global Investors | $7.574.798.407 | 30.101.551 | 3,72% | Saham |
| NORGES BANK | $6.430.543.942 | 25.554.538 | 3,16% | Saham |
| Capital World Investors | $4.826.436.854 | 19.178.966 | 2,37% | Saham |
| Capital International Investors | $3.936.357.038 | 15.638.631 | 1,93% | Saham |
| FMR LLC | $3.669.614.638 | 14.582.795 | 1,80% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3.235.535.863 | 12.854.734 | 1,59% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $2.501.249.007 | 9.939.791 | 1,23% | Saham |
| Fisher Asset Management, LLC | $2.390.069.445 | 9.497.970 | 1,17% | Saham |
| VANGUARD GROUP INC | $2.321.825.812 | 10.161.608 | 1,14% | Saham |
| AMERIPRISE FINANCIAL INC | $2.300.268.904 | 9.140.996 | 1,13% | Saham |
| UBS Group AG | $1.821.262.870 | 7.237.573 | 0,89% | Saham |
| RAYMOND JAMES FINANCIAL INC | $1.804.931.470 | 7.172.673 | 0,89% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $1.626.458.497 | 6.463.432 | 0,80% | Saham |
| BANK OF AMERICA CORP /DE/ | $1.288.677.353 | 5.121.115 | 0,63% | Saham |
| BlackRock, Inc. | $1.281.498.844 | 5.092.588 | 0,63% | Saham |
| Swiss National Bank | $1.255.358.984 | 4.988.710 | 0,62% | Saham |
| GOLDMAN SACHS GROUP INC | $1.238.268.174 | 4.920.792 | 0,61% | Saham |
| ENVESTNET ASSET MANAGEMENT INC | $1.229.678.938 | 4.886.670 | 0,60% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $1.194.403.724 | 4.746.478 | 0,59% | Saham |
| Mitsubishi UFJ Asset Management Co., Ltd. | $1.092.298.708 | 4.340.720 | 0,54% | Saham |
| LPL Financial LLC | $1.030.798.580 | 4.096.323 | 0,51% | Saham |
| National Pension Service | $1.008.968.950 | 4.009.573 | 0,50% | Saham |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.005.413.025 | 3.995.442 | 0,49% | Saham |
| Sumitomo Mitsui Trust Group, Inc. | $992.857.195 | 3.945.546 | 0,49% | Saham |
| Vanguard Global Advisers, LLC | $963.609.833 | 3.829.319 | 0,47% | Saham |
| Robeco Institutional Asset Management B.V. | $897.126.545 | 3.565.119 | 0,44% | Saham |
| Legal & General Group Plc | $895.484.594 | 3.558.594 | 0,44% | Saham |
| ALLIANCEBERNSTEIN L.P. | $890.041.939 | 4.092.335 | 0,44% | Saham |
| California Public Employees Retirement System | $862.671.241 | 3.428.196 | 0,42% | Saham |
| CANADA PENSION PLAN INVESTMENT BOARD | $817.473.174 | 3.248.582 | 0,40% | Saham |
| CITADEL ADVISORS LLC | $797.644.194 | 3.169.783 | 0,39% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $768.828.394 | 3.055.271 | 0,38% | Saham |
| BARCLAYS PLC | $739.133.865 | 2.937.267 | 0,36% | Saham |
| NORDEA INVESTMENT MANAGEMENT AB | $721.397.794 | 2.869.636 | 0,35% | Saham |
| RHUMBLINE ADVISERS | $687.895.224 | 2.733.648 | 0,34% | Saham |
| PRINCIPAL FINANCIAL GROUP INC | $667.358.842 | 2.652.038 | 0,33% | Saham |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $655.267.540 | 2.603.988 | 0,32% | Saham |
| TD Asset Management Inc | $648.811.716 | 2.578.333 | 0,32% | Saham |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $631.733.198 | 2.904.654 | 0,31% | Saham |
| PNC Financial Services Group, Inc. | $625.922.542 | 2.487.373 | 0,31% | Saham |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $584.076.068 | 2.321.078 | 0,29% | Saham |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $582.914.088 | 2.680.188 | 0,29% | Saham |
| FIFTH THIRD BANCORP | $541.376.862 | 2.151.394 | 0,27% | Saham |
| Assenagon Asset Management S.A. | $527.911.026 | 2.097.882 | 0,26% | Saham |
| JANE STREET GROUP, LLC | $520.089.552 | 2.066.800 | 0,26% | Opsi beli |
| CITADEL ADVISORS LLC | $500.839.092 | 1.990.300 | 0,25% | Opsi beli |
| JANE STREET GROUP, LLC | $499.555.728 | 1.985.200 | 0,25% | Opsi jual |
| HighTower Advisors, LLC | $495.062.218 | 1.967.343 | 0,24% | Saham |
| NEW YORK STATE COMMON RETIREMENT FUND | $485.540.135 | 1.929.503 | 0,24% | Saham |
| GQG Partners LLC | $483.559.978 | 1.921.614 | 0,24% | Saham |
| PRUDENTIAL FINANCIAL INC | $478.733.776 | 1.902.455 | 0,23% | Saham |
| Fayez Sarofim & Co | $464.570.323 | 1.846.170 | 0,23% | Saham |
| CAPTRUST FINANCIAL ADVISORS | $457.328.195 | 1.817.391 | 0,22% | Saham |
| US BANCORP \DE\ | $431.161.990 | 1.713.408 | 0,21% | Saham |
| MACKENZIE FINANCIAL CORP | $429.747.269 | 1.707.786 | 0,21% | Saham |
| AVIVA PLC | $418.894.036 | 1.664.656 | 0,21% | Saham |
| AMERICAN CENTURY COMPANIES INC | $417.685.426 | 1.659.851 | 0,21% | Saham |
| Caisse de depot et placement du Quebec | $413.100.025 | 1.641.631 | 0,20% | Saham |
| Baird Financial Group, Inc. | $408.320.931 | 1.622.639 | 0,20% | Saham |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $402.263.652 | 1.598.568 | 0,20% | Saham |
| VICTORY CAPITAL MANAGEMENT INC | $398.029.187 | 1.581.740 | 0,20% | Saham |
| Eurizon Capital SGR S.p.A. | $382.266.246 | 1.515.159 | 0,19% | Saham |
| MILLENNIUM MANAGEMENT LLC | $381.605.769 | 1.516.475 | 0,19% | Saham |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $379.803.020 | 1.509.311 | 0,19% | Saham |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $358.269.921 | 1.448.017 | 0,18% | Saham |
| APG Asset Management N.V. | $355.105.573 | 1.613.385 | 0,17% | Saham |
| CINCINNATI INSURANCE CO | $353.604.528 | 1.405.200 | 0,17% | Saham |
| CITADEL ADVISORS LLC | $352.698.624 | 1.401.600 | 0,17% | Opsi jual |
| Alecta Tjanstepension Omsesidigt | $350.097.440 | 1.393.700 | 0,17% | Saham |
| UBS Group AG | $347.253.386 | 1.379.961 | 0,17% | Opsi beli |
| ROYAL LONDON ASSET MANAGEMENT LTD | $337.822.422 | 1.342.483 | 0,17% | Saham |
| Korea Investment CORP | $324.892.907 | 1.291.102 | 0,16% | Saham |
| BLAIR WILLIAM & CO/IL | $324.076.456 | 1.287.857 | 0,16% | Saham |
| CIBC Bancorp USA Inc. | $319.137.398 | 1.268.149 | 0,16% | Saham |
| NEUBERGER BERMAN GROUP LLC | $312.155.419 | 1.240.484 | 0,15% | Saham |
| KEYBANK NATIONAL ASSOCIATION/OH | $297.253.749 | 1.181.266 | 0,15% | Saham |
| PFA Pension, Forsikringsaktieselskab | $296.007.110 | 1.176.312 | 0,15% | Saham |
| Candriam S.C.A. | $292.814.436 | 1.164.745 | 0,14% | Saham |
| BANK OF MONTREAL /CAN/ | $287.298.646 | 1.141.705 | 0,14% | Saham |
| MENORA MIVTACHIM HOLDINGS LTD. | $286.660.236 | 1.139.168 | 0,14% | Saham |
| Quantinno Capital Management LP | $286.551.564 | 1.138.736 | 0,14% | Saham |
| CITIGROUP INC | $284.177.052 | 1.129.300 | 0,14% | Opsi jual |
| D. E. Shaw & Co., Inc. | $279.166.396 | 1.109.388 | 0,14% | Saham |
| Nuveen, LLC | $278.124.451 | 1.105.247 | 0,14% | Saham |
| Public Sector Pension Investment Board | $273.989.658 | 1.088.816 | 0,13% | Saham |
| STOREBRAND ASSET MANAGEMENT AS | $271.386.191 | 1.078.470 | 0,13% | Saham |
| ProShare Advisors LLC | $270.105.595 | 1.073.381 | 0,13% | Saham |
| Aberdeen Group plc | $269.639.809 | 1.071.530 | 0,13% | Saham |
| Guinness Asset Management LTD | $261.219.378 | 1.042.337 | 0,13% | Saham |
| TRUIST FINANCIAL CORP | $259.417.636 | 1.030.908 | 0,13% | Saham |
| Cerity Partners LLC | $251.309.055 | 998.667 | 0,12% | Saham |
| Cetera Investment Advisers | $249.297.571 | 990.692 | 0,12% | Saham |
| JONES FINANCIAL COMPANIES LLLP | $246.700.034 | 973.752 | 0,12% | Saham |
| COMMONWEALTH EQUITY SERVICES, LLC | $245.375.470 | 975.105 | 0,12% | Saham |
| FEDERATED HERMES, INC. | $244.359.552 | 971.068 | 0,12% | Saham |
| SATURNA CAPITAL CORP | $240.562.538 | 958.069 | 0,12% | Saham |
Orang dalam perusahaan 38 orang dalam · 20 pejabat · 15 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Robert A. Michael | CHIEF EXECUTIVE OFFICER | 28 Feb. 2025 F | 132.821 | 0 | 0 | $0 |
| Scott T Reents | EVP, CHIEF FINANCIAL OFFICER | 14 Maret 2025 S | 11.577 | 0 | 0 | $0 |
| Nicholas Donoghoe | EVP, CHIEF BUS/STRAT OFFICER | 14 Agu 2026 M | 74.430 | 0 | 1 | $-8.177.500 |
| Azita Saleki-Gerhardt | EVP, CHIEF OPERATIONS OFFICER | 12 Agu 2025 M | 177.292 | 0 | 0 | $0 |
| Jeffrey Ryan Stewart | EVP, CHIEF COMMERCIAL OFFICER | 31 Maret 2025 M | 53.234 | 0 | 0 | $0 |
| Perry C Siatis | EVP, GC AND SECRETARY | 3 Maret 2025 D | 4.619 | 0 | 0 | $0 |
| Timothy J. Richmond | EVP, CHIEF HR OFFICER | 3 Maret 2025 S | 6.130 | 0 | 0 | $0 |
| Roopal Thakkar | EVP, R&D and CSO | 28 Feb. 2025 F | 42.276 | 0 | 0 | $0 |
| Kevin K Buckbee | SVP, CONTROLLER | 28 Feb. 2025 F | 7.797 | 0 | 0 | $0 |
| Thomas J Hudson | SVP, CSO, GLOBAL RESEARCH | 28 Feb. 2024 F | 107.267 | 0 | 0 | $0 |
| Carrie C Strom | SVP & PRES GLOBAL ALLERG AESTH | 11 Mei 2023 F | 28.024 | 0 | 0 | $0 |
| Elaine K. Sorg | SVP, US COMMERCIAL OPERATIONS | 25 April 2023 M | 35.330 | 0 | 0 | $0 |
| Brian L Durkin | VP, CONTROLLER | 28 Feb. 2023 F | 33.149 | 0 | 0 | $0 |
| Michael Severino | Vice Chairman | 23 Mei 2022 M | 152.103 | 0 | 0 | $0 |
| Henry O Gosebruch | EVP, Chief Strategy Officer | 16 Mei 2022 M | 41.623 | 0 | 0 | $0 |
| Laura J Schumacher | Vice Chairman | 25 Feb. 2022 F | 248.002 | 0 | 0 | $0 |
| Carlos Alban | Vice Chairman | 16 Nov. 2020 M | 114.899 | 0 | 0 | $0 |
| William J Chase | EVP, Finance & Administration | 26 Juni 2019 P | 169.552 | 0 | 0 | $0 |
| Thomas A. Hurwich | VP, Controller | 28 Feb. 2017 F | 62.329 | 0 | 0 | $0 |
| John M. Leonard | SVP, Chief Scientific Officer | 15 Maret 2013 M | 107.320 | 0 | 0 | $0 |
| Susan E Quaggin | Direktur | 30 Juni 2026 A | 2.525 | 0 | 0 | $0 |
| Edward J Rapp | Direktur | 30 Juni 2026 A | 45.964 | 0 | 0 | $0 |
| Frederick H Waddell | Direktur | 8 Mei 2026 A | 30.076 | 0 | 0 | $0 |
| Thomas J Falk | Direktur | 8 Mei 2026 A | 2.321 | 0 | 0 | $0 |
| Roxanne S Austin | Direktur | 8 Mei 2026 A | 39.576 | 0 | 0 | $0 |
| Robert J Alpern | Direktur | 30 Juni 2025 A | 35.646 | 0 | 0 | $0 |
| Jennifer L. Davis | Direktur | 9 Mei 2025 A | 2.525 | 0 | 0 | $0 |
| Melody B Meyer | Direktur | 9 Mei 2025 A | 16.498 | 0 | 0 | $0 |
| William H.L. Burnside | Direktur | 9 Mei 2025 A | 26.958 | 0 | 0 | $0 |
| Brett J Hart | Direktur | 9 Mei 2025 A | 19.472 | 0 | 0 | $0 |
| Glenn F Tilton | Direktur | 9 Mei 2025 A | 51.564 | 0 | 0 | $0 |
| Richard A Gonzalez | Direktur | 31 Maret 2025 G | 386.479 | 0 | 0 | $0 |
| Edward M Liddy | Direktur | 31 Maret 2022 A | 26.683 | 0 | 0 | $0 |
| Roy S Roberts | Direktur | 8 Mei 2015 A | 27.486 | 0 | 0 | $0 |
| AbbVie Inc. | Pemilik 10% | 28 Maret 2017 S | 1.190.473 | 0 | 0 | $0 |
| ABBOTT LABORATORIES | Pemilik 10% | 12 Des. 2012 J | 0 | 0 | 0 | $0 |
| Rebecca B Roberts | — | 8 Mei 2026 A | 14.846 | 0 | 0 | $0 |
| Thomas C Freyman | — | 8 Mei 2026 A | 127.869 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 1 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| AbbVie Inc. | 6 Okt. 2017 | — | Pengajuan awal | M&A / penjualan | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 301 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| FTXH · First Trust Exchange-Traded Fund VI | 7,39% | 10.640 NS | 30 Juni 2026 | N-PORT |
| IYH · iShares Trust | 7,16% | 1.056.138 SH | 21 Agu 2026 | Harian |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 6,58% | 3.464 NS | 30 April 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 6,56% | 5.317.086 SH | 19 Agu 2026 | Harian |
| HDV · iShares Trust | 6,21% | 3.641.083 SH | 21 Agu 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 6,03% | 814.750 NS | 30 April 2026 | N-PORT |
| RXL · ProShares Trust | 5,57% | 18.435 NS | 31 Mei 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 5,39% | 35.243 NS | 30 April 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 5,39% | 108.712 SH | 21 Agu 2026 | Harian |
| IXJ · iShares Trust | 4,97% | 825.161 SH | 21 Agu 2026 | Harian |
| MEDI · Harbor ETF Trust | 4,78% | 6.235 NS | 30 April 2026 | N-PORT |
| LCOW · Pacer Funds Trust | 4,28% | 4.651 NS | 30 April 2026 | N-PORT |
| FLAG · Global X Funds | 4,27% | 333 NS | 30 April 2026 | N-PORT |
| PSIL · AdvisorShares Trust | 4,14% | 7.318 NS | 30 Juni 2026 | N-PORT |
| FDV · Federated Hermes ETF Trust | 3,86% | 136.965 NS | 30 April 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 3,73% | 264.051 SH | 21 Agu 2026 | Harian |
| DIVL · Madison ETFs Trust | 3,68% | 8.786 NS | 30 Juni 2026 | N-PORT |
| USMC · Principal Exchange-Traded Funds | 3,39% | 470.441 NS | 30 Juni 2026 | N-PORT |
| AGNG · Global X Funds | 3,16% | 11.869 NS | 31 Mei 2026 | N-PORT |
| DGRO · iShares Trust | 3,04% | 5.059.458 SH | 21 Agu 2026 | Harian |
| ABOT · Abacus FCF ETF Trust | 2,85% | 594 NS | 30 April 2026 | N-PORT |
| CANC · Tema ETF Trust | 2,81% | 22.700 NS | 31 Mei 2026 | N-PORT |
| PAYR · Federated Hermes ETF Trust | 2,69% | 4.656 NS | 30 April 2026 | N-PORT |
| QDEF · FlexShares Trust | 2,66% | 66.732 NS | 30 April 2026 | N-PORT |
| QDF · FlexShares Trust | 2,63% | 264.330 NS | 30 April 2026 | N-PORT |
| SNPV · DBX ETF Trust | 2,62% | 27.726 NS | 29 Mei 2026 | N-PORT |
| BRIF · FIS Trust | 2,50% | 16.907 NS | 31 Mei 2026 | N-PORT |
| ABFL · Abacus FCF ETF Trust | 2,48% | 58.404 NS | 30 April 2026 | N-PORT |
| XT · iShares Trust | 2,47% | 372.278 SH | 21 Agu 2026 | Harian |
| DIVY · Tidal Trust I | 2,42% | 3.163 NS | 31 Mei 2026 | N-PORT |
| HRTS · Tema ETF Trust | 2,40% | 5.714 NS | 31 Mei 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 2,35% | 498 NS | 30 April 2026 | N-PORT |
| FLCC · Federated Hermes ETF Trust | 2,20% | 12.240 NS | 31 Mei 2026 | N-PORT |
| VUSE · ETF Series Solutions | 2,15% | 67.918 NS | 31 Mei 2026 | N-PORT |
| QLV · FlexShares Trust | 2,13% | 17.108 NS | 30 April 2026 | N-PORT |
| CGCV · Capital Group Conservative Equity E… | 2,13% | 171.487 NS | 31 Mei 2026 | N-PORT |
| MGV · VANGUARD WORLD FUND | 2,10% | 1.110.490 SH | 19 Agu 2026 | Harian |
| FDIV · EA Series Trust | 2,10% | 7.229 NS | 30 April 2026 | N-PORT |
| FLCG · Federated Hermes ETF Trust | 2,04% | 53.408 NS | 31 Mei 2026 | N-PORT |
| CAPE · DoubleLine ETF Trust | 2,03% | 19.271 NS | 30 Juni 2026 | N-PORT |
| BSCQ · Invesco Exchange-Traded Self-Indexe… | 1,99% | 69.180.000 | 21 Agu 2026 | Harian |
| VIG · VANGUARD SPECIALIZED FUNDS | 1,94% | 9.981.469 SH | 19 Agu 2026 | Harian |
| PJFV · PGIM ETF Trust | 1,90% | 7.518 NS | 29 Mei 2026 | N-PORT |
| SWP · Manager Directed Portfolios | 1,89% | 13.423 NS | 31 Mei 2026 | N-PORT |
| CDEI · Morgan Stanley ETF Trust | 1,88% | 1.357 NS | 30 Juni 2026 | N-PORT |
| NUDV · Nushares ETF Trust | 1,87% | 4.006 NS | 30 April 2026 | N-PORT |
| SDOG · ALPS ETF Trust | 1,87% | 118.805 NS | 31 Mei 2026 | N-PORT |
| ANEW · ProShares Trust | 1,86% | 661 NS | 31 Mei 2026 | N-PORT |
| VYM · VANGUARD WHITEHALL FUNDS | 1,85% | 7.067.444 SH | 19 Agu 2026 | Harian |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 1,82% | 54.664.000 | 21 Agu 2026 | Harian |